PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 3379343-9 1988 To determine the role of cross-linking of apoproteins to each other in the inhibition, we used the bifunctional reagent dimethylsuberimidate (DMS) to cross-link the apoproteins in HDL3. Dimethyl Suberimidate 120-140 HDL3 Homo sapiens 180-184 3379343-9 1988 To determine the role of cross-linking of apoproteins to each other in the inhibition, we used the bifunctional reagent dimethylsuberimidate (DMS) to cross-link the apoproteins in HDL3. Dimethyl Suberimidate 142-145 HDL3 Homo sapiens 180-184 8743192-6 1996 Furthermore, the effect of HDL3 was abolished after covalent modification of HDL3 with dimethylsuberimidate and was not observed in platelets from Glanzmann thrombasthenia type 1 which do not express GP IIb/IIIa, as well as in platelets preincubated with anti-GP IIb/IIIa polyclonal antibodies. Dimethyl Suberimidate 87-107 HDL3 Homo sapiens 27-31 8743192-6 1996 Furthermore, the effect of HDL3 was abolished after covalent modification of HDL3 with dimethylsuberimidate and was not observed in platelets from Glanzmann thrombasthenia type 1 which do not express GP IIb/IIIa, as well as in platelets preincubated with anti-GP IIb/IIIa polyclonal antibodies. Dimethyl Suberimidate 87-107 HDL3 Homo sapiens 77-81 1466659-2 1992 Cholesterol-loaded cells interacted with native apolipoprotein (apo) E-free high density lipoprotein3 (HDL)3 as well as with dimethyl suberimidate-modified HDL3 (DMS-HDL3). Dimethyl Suberimidate 125-146 HDL3 Homo sapiens 156-160 1466659-2 1992 Cholesterol-loaded cells interacted with native apolipoprotein (apo) E-free high density lipoprotein3 (HDL)3 as well as with dimethyl suberimidate-modified HDL3 (DMS-HDL3). Dimethyl Suberimidate 125-146 HDL3 Homo sapiens 166-170 1402404-7 1992 Efflux mediated by dimethyl suberimidate-treated HDL3, which does not interact with high affinity HDL receptors, was similar to efflux induced by native HDL3 after all fatty acid treatments. Dimethyl Suberimidate 19-40 HDL3 Homo sapiens 49-53 2397248-2 1990 The labeled HDL3 was modified by cross-linking of apoproteins with dimethylsuberimidate (DMS) to inhibit binding to HDL specific receptors. Dimethyl Suberimidate 67-87 HDL3 Homo sapiens 12-16 2397248-2 1990 The labeled HDL3 was modified by cross-linking of apoproteins with dimethylsuberimidate (DMS) to inhibit binding to HDL specific receptors. Dimethyl Suberimidate 89-92 HDL3 Homo sapiens 12-16 9633924-3 1998 The inhibitory effects of HDL3 on inositol 1,4,5-tris-phosphate formation and intracellular calcium mobilization were abolished after covalent modification of HDL3 with dimethylsuberimidate. Dimethyl Suberimidate 169-189 HDL3 Homo sapiens 26-30 9633924-3 1998 The inhibitory effects of HDL3 on inositol 1,4,5-tris-phosphate formation and intracellular calcium mobilization were abolished after covalent modification of HDL3 with dimethylsuberimidate. Dimethyl Suberimidate 169-189 HDL3 Homo sapiens 159-163 1930148-7 1991 Covalent modification of the apoproteins of HDL3 with dimethyl suberimidate or tetranitromethane did not inhibit the HDL3-induced rise in [Ca2+]i. Dimethyl Suberimidate 54-75 HDL3 Homo sapiens 44-48 1892880-4 1991 At identical concentrations, HDL3 and dimethylsuberimidate treated-HDL3 promoted similar efflux, suggesting that efflux did not depend on specific binding of HDL3 to the cell surface. Dimethyl Suberimidate 38-58 HDL3 Homo sapiens 67-71 1892880-4 1991 At identical concentrations, HDL3 and dimethylsuberimidate treated-HDL3 promoted similar efflux, suggesting that efflux did not depend on specific binding of HDL3 to the cell surface. Dimethyl Suberimidate 38-58 HDL3 Homo sapiens 67-71